HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fahn, H. J. Articles by Chien, K. Y. Search for Related Content PubMed PubMed Citation Articles by Fahn, H. J. Articles by Chien, K. Y.

The Annals of Thoracic Surgery, Vol 57, 677-681, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Tumor recurrence in long-term survivors after treatment of carcinoma of the esophagus

HJ Fahn, LS Wang, BS Huang, MH Huang and KY Chien
Department of Surgery, Veterans General Hospital-Taipei, Taiwan, Republic of China.

To evaluate the status of tumor recurrence and the possible factors relevant to tumor recurrence among patients who survived more than 5 years after subtotal esophagectomy for the treatment of squamous cell carcinoma of the esophagus, a total of 104 patients who received treatment between 1959 and 1986 were reviewed. In 18 of these 104 patients, local or distant tumor recurrence developed, for a tumor recurrence rate of 17.3%. Eleven (61.1%) of these 18 patients eventually died of carcinomatosis despite further radiotherapy or chemotherapy, or both, and 4 patients with the disease are still alive. Three patients continue to survive after aggressive therapy was instituted for control of the locally recurrent tumor. Sixty-nine of the 104 patients are alive without tumor recurrence after the initial esophagectomy, and the remaining 17 patients died of miscellaneous causes. Tumor recurrence appears to be the most important factor affecting the prognosis in long-term survivors with resectable esophageal carcinoma. Among the 11 patients who died of tumor recurrence, 10 died within 5 to 9 years of their esophagectomy. The incidence of various modes of tumor recurrence among these 18 patients was as follows: blood-borne metastasis, 61%; lymph node recurrence, 33%; and locoregional organ recurrence, 33%. Factors that may be pertinent to a higher tumor recurrence rate include male sex, moderate to poor tumor differentiation, the presence of lymph node metastasis, and late stage of disease (stage IIb or worse). However, we could not find any statistical significance among these possible factors.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				P.-K. Hsu, A. F.-Y. Li, Y.-C. Wang, C.-C. Hsieh, M.-H. Huang, W.-H. Hsu, and H.-S. Hsu Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1029 - 1035. [Abstract] [Full Text] [PDF]

				T. J. Kim, K. H. Lee, Y. H. Kim, S. W. Sung, S. Jheon, S.-k. Cho, and K. W. Lee Postoperative Imaging of Esophageal Cancer: What Chest Radiologists Need to Know RadioGraphics, March 1, 2007; 27(2): 409 - 429. [Abstract] [Full Text] [PDF]

				Y.-G. Goan, H.-K. Hsu, H.-C. Chang, Y.-P. Chou, K.-H. Chiang, and J.-T. Cheng Deregulated P21WAF1 Overexpression Impacts Survival of Surgically Resected Esophageal Squamous Cell Carcinoma Patients Ann. Thorac. Surg., September 1, 2005; 80(3): 1007 - 1016. [Abstract] [Full Text] [PDF]

				J.-M. Lee, M.-T. Wu, Y.-C. Lee, S.-Y. Yang, J.-S. Chen, H.-H. Hsu, P.-M. Huang, S.-W. Kuo, C.-J. Lee, and C.-J. Chen Association of GSTP1 Polymorphism and Survival for Esophageal Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4749 - 4753. [Abstract] [Full Text] [PDF]

				S. Nagatani, Y. Shimada, Z. Li, J. Kaganoi, T. Kan, M. Maeda, G. Watanabe, and M. Imamura Validation of Intra-operative Detection of Paratracheal Lymph Node Metastasis Using Real-time RT-PCR Targeting Esophageal Squamous Cell Carcinoma Jpn. J. Clin. Oncol., November 1, 2003; 33(11): 549 - 555. [Abstract] [Full Text] [PDF]

				L.-S. Wang, K.-C. Chow, W.-Y. Li, C.-C. Liu, Y.-C. Wu, and M.-H. Huang Clinical Significance of Serum Soluble Interleukin 2 Receptor-{{alpha}} in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1445 - 1451. [Abstract] [Full Text]